FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...
CWRU has a decades-long history of research into pyruvate dehydrogenase complex deficiency (PDCD). The pyruvate dehydrogenase complex (PDC) is a multiple enzyme complex in the shape of a pentagonal ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Oct. 4, 2022 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the pivotal Phase 3 ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, Jan. 28, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug ...
DCA is an investigational product, that if approved, will be used with a proprietary dose-related genetic test to treat an orphan pediatric mitochondrial disease, Pyruvate Dehydrogenase Complex ...
March 18, 2024 – Cure Mito Foundation and Hope for PDCD foundation, both patient-led foundations focused on advancing research and supporting families affected by Leigh syndrome and Pyruvate ...
GRAND RAPIDS, Mich. — A West Michigan family is spreading the word about their daughter's rare diagnosis in the hopes of funding research about Pyruvate Dehydrogenase Complex Deficiency (PDCD). Andrew ...
ROSWELL, Ga. and ST. PETERSBURG, Fla., April 26, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a partnership with InformedDNA®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results